The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States

Open Access

Peer-reviewed

Research Article

Bruce Wang ,

* E-mail: bruce.wang@alscg.com

Affiliation Elysia Group, LLC, New York, New York, United States of America
⨯
Joshua A. Roth,

Affiliations Department of Pharmacy, University of Washington, Seattle, Washington, United States of America, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
⨯
Hiep Nguyen,

Affiliation AstraZeneca, Fort Washington, Pennsylvania, United States of America
⨯
Eugene Felber,

Affiliation Bristol-Myers Squibb Company, New York, New York, United States of America
⨯
Wes Furnback,

Affiliation Elysia Group, LLC, New York, New York, United States of America
⨯
Louis P. Garrison

Affiliation Department of Pharmacy, University of Washington, Seattle, Washington, United States of America
⨯

Reader Comments (0)

Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
HbA1c
Is the Subject Area "HbA1c" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Monte Carlo method
Is the Subject Area "Monte Carlo method" applicable to this article?

Thanks for your feedback.
Simulation and modeling
Is the Subject Area "Simulation and modeling" applicable to this article?

Thanks for your feedback.